Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10147425 | 0.92 | GRIA1 (0.50) | GRIA1RENHTR1AKCNH2LMNA | |
| SCHEMBL10141254 | 0.84 | GRIA1 (0.57) | GRIA1PPARARELACA1CA2 | |
| SCHEMBL14652011 | 0.83 | GRIA1 (0.75) | GRIA1PPARAHTR1ALMNACA1 | |
| SCHEMBL19996825 | 0.83 | GRIA1 (0.43) | GRIA1RENHTR1AKCNH2KMT2A | |
| SCHEMBL18949031 | 0.82 | GRIA1 (0.54) | GRIA1PPARARELACA1CA2 | |
| SCHEMBL28631180 | 0.79 | GRIA1 (0.50) | GRIA1PPARALMNACA1CA2 | |
| SCHEMBL28624948 | 0.79 | GRIA1 (0.50) | GRIA1PPARALMNACA1CA2 | |
| SCHEMBL1728264 | 0.79 | GRIA1 (0.50) | GRIA1PPARALMNACA1CA2 | |
| SCHEMBL12967013 | 0.79 | GRIA1 (0.50) | GRIA1PPARALMNACA1CA2 | |
| SCHEMBL1728036 | 0.79 | GRIA1 (0.50) | GRIA1PPARALMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110250172-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | GRIA1 4165/4885REN 3394/4885PPARA 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.